» Articles » PMID: 39267774

Bisecting GlcNAc Modification Reverses the Chemoresistance Via Attenuating the Function of P-gp

Overview
Journal Theranostics
Date 2024 Sep 13
PMID 39267774
Authors
Affiliations
Soon will be listed here.
Abstract

Chemoresistance is a key factor contributing to the failure of anti-breast cancer chemotherapy. Although abnormal glycosylation is closely correlated with breast cancer progression, the function of glycoconjugates in chemoresistance remains poorly understood. Levels and regulatory roles of bisecting N-acetylglucosamine (GlcNAc) in chemoresistant breast cancer cells were determined in vitro and in vivo. Glycoproteomics guided identification of site-specific bisecting GlcNAc on P-glycoprotein (P-gp). Co-immunoprecipitation coupled mass spectrometry (Co-IP-MS) and proximity labelling MS identified the interactome of P-gp, and the biological function of site-specific bisecting GlcNAc was investigated by site/truncation mutation and structural simulations. Bisecting GlcNAc levels were reduced in chemoresistant breast cancer cells, accompanied by an enhanced expression of P-gp. Enhanced bisecting GlcNAc effectively reversed chemoresistance. Mechanical study revealed that bisecting GlcNAc impaired the association between Ezrin and P-gp, leading to a decreased expression of membrane P-gp. Bisecting GlcNAc suppressed VPS4A-mediated P-gp recruitment into microvesicles, and chemoresistance transmission. Structural dynamics analysis suggested that bisecting GlcNAc at Asn494 introduced structural constraints that rigidified the conformation and suppressed the activity of P-gp. Our findings highlight the crucial role of bisecting GlcNAc in chemoresistance and suggest the possibility of reversing chemoresistance by modulating the specific glycosylation in breast cancer therapy.

Citing Articles

Proximity Labeling-Based Identification of MGAT3 Substrates and Revelation of the Tumor-Suppressive Role of Bisecting GlcNAc in Breast Cancer via GLA Degradation.

Wang B, He X, Zhou Y, Tan Z, Li X, Guan F Cells. 2025; 14(2).

PMID: 39851531 PMC: 11764451. DOI: 10.3390/cells14020103.

References
1.
Cheng L, Cao L, Wu Y, Xie W, Li J, Guan F . Bisecting N-Acetylglucosamine on EGFR Inhibits Malignant Phenotype of Breast Cancer via Down-Regulation of EGFR/Erk Signaling. Front Oncol. 2020; 10:929. PMC: 7308504. DOI: 10.3389/fonc.2020.00929. View

2.
Ferreira J, Peixoto A, Neves M, Gaiteiro C, Reis C, Assaraf Y . Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation. Drug Resist Updat. 2016; 24:34-54. DOI: 10.1016/j.drup.2015.11.003. View

3.
Muralidharan-Chari V, Clancy J, Plou C, Romao M, Chavrier P, Raposo G . ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol. 2009; 19(22):1875-85. PMC: 3150487. DOI: 10.1016/j.cub.2009.09.059. View

4.
Tan Z, Cao L, Wu Y, Wang B, Song Z, Yang J . Bisecting GlcNAc modification diminishes the pro-metastatic functions of small extracellular vesicles from breast cancer cells. J Extracell Vesicles. 2020; 10(1):e12005. PMC: 7710122. DOI: 10.1002/jev2.12005. View

5.
Maeser D, Gruener R, Huang R . oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021; 22(6). PMC: 8574972. DOI: 10.1093/bib/bbab260. View